Overview

* Steris fiscal Q1 2026 revenue rises 9% to $1.4 bln

* Adjusted EPS for fiscal Q1 beats analyst expectations, per LSEG data

* Co raises fiscal 2026 revenue outlook, expecting 8-9% growth

Outlook

* Steris ( STE ) expects fiscal 2026 revenue to increase 8-9%

* Still sees Adjusted EPS from continuing operations of $9.90 to $10.15

* Company anticipates $820 mln free cash flow for fiscal 2026

* Steris ( STE ) projects capital expenditures of $375 mln for fiscal 2026

* Company sees tariffs reducing pre-tax profit by $45 mln

Result Drivers

* FOREIGN CURRENCY - Revenue benefited from favorable foreign currency impacts, expected to continue throughout fiscal yr, per CEO Dan Carestio

* HEALTHCARE SEGMENT - Healthcare revenue grew 8%, driven by 13% service revenue growth and improved volume and price

* AST SEGMENT - Applied Sterilization Technologies revenue increased 13%, with significant growth in capital equipment revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $2.34 $2.26 (8

Adjusted Analysts

EPS )

Q1 Beat $231.20 $222.20

Adjusted mln mln (5

Net Analysts

Income )

Q1 $1.40

Revenue bln

continui

ng

operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for STERIS plc ( STE ) is $278.00, about 19.5% above its August 5 closing price of $223.87

* The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)